Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Schwartz

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 24, 2020
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedemaJonathan A Bernstein, Lawrence Schwartz, William Yang, et al.
Clinical Prostate Cancer|January 8, 2005
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapseDarko Pucar, Jason A Koutcher, Ankoor Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris, Timothy Akhurst, Steven M Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah, Ramesh K Ramanathan, David H Ilson, et al.
Gastrointestinal Cancer Research : GCR|January 8, 2013
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular CarcinomaCelina Ang, Eileen M O'Reilly, Richard D Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsWilliam P Tew, Michael Gordon, John Murren, et al.
Clinical Nuclear Medicine|February 29, 2020
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With PembrolizumabRandy Yeh, Megan H Trager, Emanuelle M Rizk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumorsMichael J Morris, Neeta Pandit-Taskar, Chaitanya R Divgi, et al.
Annals of Surgery|April 1, 2008
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastasesAnne M Covey, Karen T Brown, William R Jarnagin, et al.
Cancer|April 28, 2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMichael J Morris, Oren Smaletz, David Solit, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 24, 2020
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedemaJonathan A Bernstein, Lawrence Schwartz, William Yang, et al.
Clinical Prostate Cancer|January 8, 2005
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapseDarko Pucar, Jason A Koutcher, Ankoor Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris, Timothy Akhurst, Steven M Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah, Ramesh K Ramanathan, David H Ilson, et al.
Gastrointestinal Cancer Research : GCR|January 8, 2013
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular CarcinomaCelina Ang, Eileen M O'Reilly, Richard D Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsWilliam P Tew, Michael Gordon, John Murren, et al.
Clinical Nuclear Medicine|February 29, 2020
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With PembrolizumabRandy Yeh, Megan H Trager, Emanuelle M Rizk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumorsMichael J Morris, Neeta Pandit-Taskar, Chaitanya R Divgi, et al.
Annals of Surgery|April 1, 2008
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastasesAnne M Covey, Karen T Brown, William R Jarnagin, et al.
Cancer|April 28, 2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMichael J Morris, Oren Smaletz, David Solit, et al.
Pageof 9